Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank-Reference-Cited by-同舟云学术

Validation of a Polygenic Score for Beta-Blocker Survival Benefit in Patients With Heart Failure Using the United Kingdom Biobank

Published:2023-04 Issue:2 Volume:16 Page:
ISSN:2574-8300
Container-title:Circulation: Genomic and Precision Medicine
language:en
Short-container-title:Circ: Genomic and Precision Medicine

Author:

Lanfear David E.¹²^ORCID,Luzum Jasmine A.¹³^ORCID,She Ruicong⁴,Li Jia⁴^ORCID,Sabbah Hani N.²^ORCID,Zeld Nicole¹^ORCID,Liu Bin⁴^ORCID,Peterson Edward⁴,Keoki Williams L.¹^ORCID

Affiliation:

1. Center for Individualized and Genomic Medicine Research (CIGMA), Department of Internal Medicine, Henry Ford Hospital, Detroit, MI (D.E.L., J.A.L., N.Z., L.K.W.).

2. Heart and Vascular Institute (D.E.L., H.N.S.), Henry Ford Health System, Detroit, MI.

3. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI (J.A.L.).

4. Department of Public Health Sciences (R.S., J.L., B.L., E.P.), Henry Ford Health System, Detroit, MI.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference5 articles.

1. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction

2. Pharmacogenetics in Chronic Heart Failure: New Developments and Current Challenges

3. Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure

4. Association of β-Blocker Exposure With Outcomes in Heart Failure Differs Between African American and White Patients

5. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenomics polygenic risk score: Ready or not for prime time?;Clinical and Translational Science;2024-07-30

2. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy;Clinical Pharmacology & Therapeutics;2024-07

3. Using Omics to Identify Novel Therapeutic Targets in Heart Failure;Circulation: Genomic and Precision Medicine;2024-06

4. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment;Journal of Internal Medicine;2024-02-11

5. Emerging trends in pharmacogenomics: from common variant associations toward comprehensive genomic profiling;Human Genomics;2023-11-24